Observe Medical ASA: Redelivery of lent shares to persons closely associated with primary insiders and mandatory notification of trade
Observe Medical ASA (OBSRV) · publisert 2024-07-02 09:47 · vis på NewsWeb
Transaksjoner
| Person | Rolle | Type | Volum | Pris | Dato | ISIN | Handelsplass | Tolket via |
|---|---|---|---|---|---|---|---|---|
| Ingerø Reiten Investment Company AS nærstående | Close associate of primary insider and chair of the board of Observe Medical ASA, Terje Bakken | other | 37 300 000 | 0 NOK | 2024-07-02 | NO0010865009 | Outside a trading venue 20065054/1 2 | rules · til gjennomgang |
| ELI AS nærstående | Close associate of primary insider and member of the board of Observe Medical ASA, Eskild Endrerud | other | 837 038 | 0 NOK | 2024-07-02 | NO0010865009 | Outside a trading venue | rules · til gjennomgang |
Vedlegg
- Appendix_Notification_of_Transaction_by_Close_Associates_Redelivery_of_lent_shares_20086997_1.pdf (tekst hentet ut)
Meldingstekst
Oslo, 2 July 2024
Reference is made to the stock exchange announcement by Observe Medical ASA
("Observe Medical" or the "Company", OSE ticker: OBSVR) on 24 June 2024 (the
"Announcement"), regarding share lending by Ingerø Reiten Investment Company AS
and ELI AS(jointly the "Share Lenders")in connection with the private placement
of new shares in the Company (the "Private Placement").
The share capital increase pertaining to tranche 1 of the Private Placement has
now been registered, as announced by the Company earlier today, and the shares
that were lent by each of the Share Lenders have been redelivered.
Following the return of the lent shares, Ingerø Reiten Investment Company AS
holds 37,384,437 shares in the Company (representing approximately 16,34% of the
issued share capital and votes). Consequently, Ingerø Reiten Investment Company
AS' shareholding has crossed the 15% threshold pursuant to Section 4-2 (1) cf.
(3) of the Norwegian Securities Trading Act.
For more information about the redelivery of the lent shares, see the attached
forms.
This information is subject to disclosure requirements pursuant to Article 19 of
Regulation EU 596/2014 (the EU Market Abuse Regulation) and Sections 4-2 and 5
-12 of the Norwegian Securities Trading Act.
For further information, please contact:
Jørgen Mann, Interim CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com
Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com
About Observe Medical:
Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.
The Company seeks to drive growth by leveraging its expertise in sales and
commercialisation of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.
The Company is headquartered in Oslo, Norway.
Further information is available at www.observemedical.com.